|
Synonyms: GSK'227 | GSK5764227 | HS-20093 | Ris-Rez
Compound class:
Antibody
Comment: Risvutatug rezetecan (GSK5764227, formerly HS-20093; Ris-Rez) is an antibody-drug congugate that targets a camptothecin derived topoisomerase I inhibitor to (tumour) cells expressing CD276 (B7-H3) [2-3,5]. Peptide sequences for risvutatug's heavy and light chains are claimed in Hansoh patent US10899837B2, and these form the antibody named h1702 therein [4].
Ligand Activity Visualisation ChartsThese are box plot that provide a unique visualisation, summarising all the activity data for a ligand taken from ChEMBL and GtoPdb across multiple targets and species. Click on a plot to see the median, interquartile range, low and high data points. A value of zero indicates that no data are available. A separate chart is created for each target, and where possible the algorithm tries to merge ChEMBL and GtoPdb targets by matching them on name and UniProt accession, for each available species. However, please note that inconsistency in naming of targets may lead to data for the same target being reported across multiple charts. ✖ |
| References |
|
1. Duan J, Sun Y, Wang Q, Xing L, Wu L, Han L, Chen J, Liu B, Lu P, Shi H et al.. (2026)
HS-20093, a B7-H3-targeted antibody-drug conjugate in lung cancer: Results from the ARTEMIS-001 phase 1a/b trial. Cancer Cell, 44 (4): 846-857.e3. [PMID:41791381] |
|
2. Fabrizio FP, Muscarella LA, Rossi A. (2024)
B7-H3/CD276 and small-cell lung cancer: What's new?. Transl Oncol, 39: 101801. [PMID:37865049] |
|
3. Feustel K, Martin J, Falchook GS. (2024)
B7-H3 Inhibitors in Oncology Clinical Trials: A Review. J Immunother Precis Oncol, 7 (1): 53-66. [PMID:38327753] |
|
4. Gu J, Wang X, Ye X, Yang L, Zhang T, Tao W, Zhang L. (2021)
B7-H3 antibody, antigen-binding fragment thereof and medical use thereof. Patent number: US10899837B2. Assignee: Hansoh Shanghai Healthtech Co Ltd, Changzhou Hansoh Pharmaceutical Co Ltd. Priority date: 30/03/2018. Publication date: 26/01/2021. |
|
5. Wang J, Jiang H, Niu J, Liu L, Wu Y, Shi J, Liu L, Yin S, Feng C, Zhang L et al.. (2026)
Efficacy and safety of B7-H3-targeted antibody-drug conjugates in previously treated small cell lung cancer: a systematic review and meta-analysis with a contextual comparison to topotecan. Front Immunol, 17: 1907324. [PMID:42661867] |